| mRNA |
nelarabine |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
4e-07 |
| mRNA |
tacedinaline |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
6e-07 |
| mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
2e-06 |
| mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
4e-06 |
| mRNA |
barasertib |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
1e-05 |
| mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
-0.24 |
1e-05 |
| mRNA |
tipifarnib |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
1e-05 |
| mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
1e-05 |
| mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
2e-05 |
| mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
3e-05 |